HawkInsight

  • Contact Us
  • App
  • English

Bonnet BioTherapeutics and Rorschach I LLC merge into Hyperliquid Strategies

Online reports that Sonnet BioTherapeutics, Inc. Has agreed to merge with Rorschach I LLC to become Hyperliquid Strategies, Inc., The company will launch a HYPE reserve strategy. After the transaction is completed, the new entity is expected to hold 12.6 million HYPE tokens and US$305 million in cash, with a total valuation of US$888 million.

Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.

NewFlashHawk Insight
More